De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Prostatype Genomics Beheer

Beheer criteriumcontroles 1/4

De CEO Prostatype Genomics' is Fredrik Rickman, benoemd in Jan2017, heeft een ambtstermijn van 7.75 jaar. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde SEK 2.28K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4 jaar.

Belangrijke informatie

Fredrik Rickman

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

CEO

Fredrik Rickman

7.8yrs

Tenure

Mr. Fredrik Rickman (Previously Fredrik Rickman) has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Fredrik Rickman	CEO & MD	7.8yrs	geen gegevens	0.018% SEK 2.5k
Anders Koch	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
George Skinner	Vice President Commercial operations	no data	geen gegevens	geen gegevens
Emelie Berglund	Chief Technology Officer	1.9yrs	geen gegevens	0.0012% SEK 166.7
Nicklas Rosendal	Communications Director	3.1yrs	geen gegevens	geen gegevens
Joakim Soderin	Chief Auditor	2.3yrs	geen gegevens	geen gegevens
Gerald Andriole	Global Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens
Steven Gaal	President US operations	1.8yrs	geen gegevens	geen gegevens
Katarina Sjöberg	QA & RA Manager	1.8yrs	geen gegevens	geen gegevens
Mats Bergström	Sales Director of EMEA	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van PROGEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anders Lundberg	Independent Chairman of the Board	7.8yrs	geen gegevens	geen gegevens
Mattias Prage	Independent Director	2.3yrs	geen gegevens	geen gegevens
Hakan Englund	Independent Director	5.8yrs	geen gegevens	0.85% SEK 122.7k
Michael Haggman	Independent Director	6.8yrs	geen gegevens	4.21% SEK 604.5k
Rolf Skoglund	Member of Advisory Board	no data	geen gegevens	geen gegevens
Jörgen Dahlström	Independent Director	less than a year	geen gegevens	0.010% SEK 1.4k
Johan Waldhe	Director	less than a year	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van PROGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Prostatype Genomics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought kr821k worth of stock

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

Recent updates

Independent Director recently bought kr821k worth of stock

Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.

First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala

Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®

Prostatype Genomics AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics

Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)

New major risk - Share price stability

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Second quarter 2023 earnings: Revenues miss analyst expectations

Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023

Now 26% undervalued after recent price drop

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

First quarter 2023 earnings released

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)

Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023

Prostatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

Prostatype Genomics Appoints Steven Gaal as President

Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022

Prostatype Genomics Announces Management Changes

Prostatype Shows Strong Data in Asian Pilot Study

Second quarter 2022 earnings released

High number of new directors

Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the Board

First quarter 2022 earnings released

Insufficient new directors

Prostatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

CEO & MD recently bought kr72k worth of stock

Insider recently bought kr108k worth of stock

Third quarter 2021 earnings released

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.

Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)

Prostatype Genomics AB (publ) to Report Q4, 2020 Results on May 17, 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur